Lifecore biomedical, inc. receives notice from nasdaq regarding delayed quarterly report

Chaska, minn., april 19, 2024 (globe newswire) -- lifecore biomedical, inc. (nasdaq: lfcr) (the “company”) announced today that, on april 15, 2024, the company received a notification letter (the “notice”) from the listing qualifications department of the nasdaq stock market llc (“nasdaq”) indicating that, as a result of the company's delay in filing its quarterly report on form 10-q for the fiscal quarter ended february 25, 2024 (the “q3 form 10-q”) and its continued delay in filing its quarterly report on form 10-q for the quarterly periods ended august 27, 2023 and november 29, 2023 (the “q1 form 10-q” and “q2 form 10-q,” respectively, and together with the q3 form 10-q, the “filings”) with the securities and exchange commission (the “sec”), the company continues not to be in compliance with the requirements for continued listing under nasdaq listing rule 5250(c)(1) (the “listing rule”), and that the nasdaq hearings panel would consider the delinquency in the filing of the q3 form 10-q in rendering its determination regarding the company's continued listing on nasdaq global select market.
LFCR Ratings Summary
LFCR Quant Ranking